Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia
Summary A total of 23 patients with high-risk acute myelogenous leukemia (AML) at diagnosis (2 patients), relapsing AML (14) or resistant AML (6) were treated with 25 μg/kg i. v. plicamycin every other day for 3 weeks and 500–4,000 mg hydroxyurea per day p. o. according to the WBC count. Aplasia was...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1989 |
|---|
| Umfang: |
3 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: Cancer chemotherapy and pharmacology - 1978, 25(1989) vom: März, Seite 223-225 |
| Übergeordnetes Werk: |
volume:25 ; year:1989 ; month:03 ; pages:223-225 ; extent:3 |
| Links: |
|---|
| Katalog-ID: |
NLEJ203001397 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ203001397 | ||
| 003 | DE-627 | ||
| 005 | 20230505223723.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070528s1989 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ203001397 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia |
| 264 | 1 | |c 1989 | |
| 300 | |a 3 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Summary A total of 23 patients with high-risk acute myelogenous leukemia (AML) at diagnosis (2 patients), relapsing AML (14) or resistant AML (6) were treated with 25 μg/kg i. v. plicamycin every other day for 3 weeks and 500–4,000 mg hydroxyurea per day p. o. according to the WBC count. Aplasia was observed in only two patients. Severe extrahematologic toxicity included sepsis (four cases), vomiting (four patients), toxic hepatitis (three cases), and fibrinopenia (one patient). No partial or complete responses were observed. The 95% confidence interval limit of the overall response rate (CR+PR) was 0–14%. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Archimbaud, Eric |4 oth | |
| 700 | 1 | |a Troncy, Jacques |4 oth | |
| 700 | 1 | |a Sebban, Catherine |4 oth | |
| 700 | 1 | |a Guyotat, Denis |4 oth | |
| 700 | 1 | |a Devaux, Yves |4 oth | |
| 700 | 1 | |a French, Martine |4 oth | |
| 700 | 1 | |a Moriceau, Michel |4 oth | |
| 700 | 1 | |a Viala, Jean-Jacques |4 oth | |
| 700 | 1 | |a Fiere, Denis |4 oth | |
| 773 | 0 | 8 | |i in |t Cancer chemotherapy and pharmacology |d 1978 |g 25(1989) vom: März, Seite 223-225 |w (DE-627)NLEJ188987932 |w (DE-600)1458488-8 |x 1432-0843 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:1989 |g month:03 |g pages:223-225 |g extent:3 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/BF00689589 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 1989 |c 3 |h 223-225 |g 3 | ||
| matchkey_str |
article:14320843:1989----::hsitilflcmcnnhdoyranctme |
|---|---|
| hierarchy_sort_str |
1989 |
| publishDate |
1989 |
| allfields |
(DE-627)NLEJ203001397 DE-627 ger DE-627 rakwb eng Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia 1989 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary A total of 23 patients with high-risk acute myelogenous leukemia (AML) at diagnosis (2 patients), relapsing AML (14) or resistant AML (6) were treated with 25 μg/kg i. v. plicamycin every other day for 3 weeks and 500–4,000 mg hydroxyurea per day p. o. according to the WBC count. Aplasia was observed in only two patients. Severe extrahematologic toxicity included sepsis (four cases), vomiting (four patients), toxic hepatitis (three cases), and fibrinopenia (one patient). No partial or complete responses were observed. The 95% confidence interval limit of the overall response rate (CR+PR) was 0–14%. Springer Online Journal Archives 1860-2002 Archimbaud, Eric oth Troncy, Jacques oth Sebban, Catherine oth Guyotat, Denis oth Devaux, Yves oth French, Martine oth Moriceau, Michel oth Viala, Jean-Jacques oth Fiere, Denis oth in Cancer chemotherapy and pharmacology 1978 25(1989) vom: März, Seite 223-225 (DE-627)NLEJ188987932 (DE-600)1458488-8 1432-0843 nnns volume:25 year:1989 month:03 pages:223-225 extent:3 http://dx.doi.org/10.1007/BF00689589 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 25 1989 3 223-225 3 |
| spelling |
(DE-627)NLEJ203001397 DE-627 ger DE-627 rakwb eng Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia 1989 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary A total of 23 patients with high-risk acute myelogenous leukemia (AML) at diagnosis (2 patients), relapsing AML (14) or resistant AML (6) were treated with 25 μg/kg i. v. plicamycin every other day for 3 weeks and 500–4,000 mg hydroxyurea per day p. o. according to the WBC count. Aplasia was observed in only two patients. Severe extrahematologic toxicity included sepsis (four cases), vomiting (four patients), toxic hepatitis (three cases), and fibrinopenia (one patient). No partial or complete responses were observed. The 95% confidence interval limit of the overall response rate (CR+PR) was 0–14%. Springer Online Journal Archives 1860-2002 Archimbaud, Eric oth Troncy, Jacques oth Sebban, Catherine oth Guyotat, Denis oth Devaux, Yves oth French, Martine oth Moriceau, Michel oth Viala, Jean-Jacques oth Fiere, Denis oth in Cancer chemotherapy and pharmacology 1978 25(1989) vom: März, Seite 223-225 (DE-627)NLEJ188987932 (DE-600)1458488-8 1432-0843 nnns volume:25 year:1989 month:03 pages:223-225 extent:3 http://dx.doi.org/10.1007/BF00689589 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 25 1989 3 223-225 3 |
| allfields_unstemmed |
(DE-627)NLEJ203001397 DE-627 ger DE-627 rakwb eng Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia 1989 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary A total of 23 patients with high-risk acute myelogenous leukemia (AML) at diagnosis (2 patients), relapsing AML (14) or resistant AML (6) were treated with 25 μg/kg i. v. plicamycin every other day for 3 weeks and 500–4,000 mg hydroxyurea per day p. o. according to the WBC count. Aplasia was observed in only two patients. Severe extrahematologic toxicity included sepsis (four cases), vomiting (four patients), toxic hepatitis (three cases), and fibrinopenia (one patient). No partial or complete responses were observed. The 95% confidence interval limit of the overall response rate (CR+PR) was 0–14%. Springer Online Journal Archives 1860-2002 Archimbaud, Eric oth Troncy, Jacques oth Sebban, Catherine oth Guyotat, Denis oth Devaux, Yves oth French, Martine oth Moriceau, Michel oth Viala, Jean-Jacques oth Fiere, Denis oth in Cancer chemotherapy and pharmacology 1978 25(1989) vom: März, Seite 223-225 (DE-627)NLEJ188987932 (DE-600)1458488-8 1432-0843 nnns volume:25 year:1989 month:03 pages:223-225 extent:3 http://dx.doi.org/10.1007/BF00689589 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 25 1989 3 223-225 3 |
| allfieldsGer |
(DE-627)NLEJ203001397 DE-627 ger DE-627 rakwb eng Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia 1989 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary A total of 23 patients with high-risk acute myelogenous leukemia (AML) at diagnosis (2 patients), relapsing AML (14) or resistant AML (6) were treated with 25 μg/kg i. v. plicamycin every other day for 3 weeks and 500–4,000 mg hydroxyurea per day p. o. according to the WBC count. Aplasia was observed in only two patients. Severe extrahematologic toxicity included sepsis (four cases), vomiting (four patients), toxic hepatitis (three cases), and fibrinopenia (one patient). No partial or complete responses were observed. The 95% confidence interval limit of the overall response rate (CR+PR) was 0–14%. Springer Online Journal Archives 1860-2002 Archimbaud, Eric oth Troncy, Jacques oth Sebban, Catherine oth Guyotat, Denis oth Devaux, Yves oth French, Martine oth Moriceau, Michel oth Viala, Jean-Jacques oth Fiere, Denis oth in Cancer chemotherapy and pharmacology 1978 25(1989) vom: März, Seite 223-225 (DE-627)NLEJ188987932 (DE-600)1458488-8 1432-0843 nnns volume:25 year:1989 month:03 pages:223-225 extent:3 http://dx.doi.org/10.1007/BF00689589 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 25 1989 3 223-225 3 |
| allfieldsSound |
(DE-627)NLEJ203001397 DE-627 ger DE-627 rakwb eng Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia 1989 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary A total of 23 patients with high-risk acute myelogenous leukemia (AML) at diagnosis (2 patients), relapsing AML (14) or resistant AML (6) were treated with 25 μg/kg i. v. plicamycin every other day for 3 weeks and 500–4,000 mg hydroxyurea per day p. o. according to the WBC count. Aplasia was observed in only two patients. Severe extrahematologic toxicity included sepsis (four cases), vomiting (four patients), toxic hepatitis (three cases), and fibrinopenia (one patient). No partial or complete responses were observed. The 95% confidence interval limit of the overall response rate (CR+PR) was 0–14%. Springer Online Journal Archives 1860-2002 Archimbaud, Eric oth Troncy, Jacques oth Sebban, Catherine oth Guyotat, Denis oth Devaux, Yves oth French, Martine oth Moriceau, Michel oth Viala, Jean-Jacques oth Fiere, Denis oth in Cancer chemotherapy and pharmacology 1978 25(1989) vom: März, Seite 223-225 (DE-627)NLEJ188987932 (DE-600)1458488-8 1432-0843 nnns volume:25 year:1989 month:03 pages:223-225 extent:3 http://dx.doi.org/10.1007/BF00689589 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 25 1989 3 223-225 3 |
| language |
English |
| source |
in Cancer chemotherapy and pharmacology 25(1989) vom: März, Seite 223-225 volume:25 year:1989 month:03 pages:223-225 extent:3 |
| sourceStr |
in Cancer chemotherapy and pharmacology 25(1989) vom: März, Seite 223-225 volume:25 year:1989 month:03 pages:223-225 extent:3 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Cancer chemotherapy and pharmacology |
| authorswithroles_txt_mv |
Archimbaud, Eric @@oth@@ Troncy, Jacques @@oth@@ Sebban, Catherine @@oth@@ Guyotat, Denis @@oth@@ Devaux, Yves @@oth@@ French, Martine @@oth@@ Moriceau, Michel @@oth@@ Viala, Jean-Jacques @@oth@@ Fiere, Denis @@oth@@ |
| publishDateDaySort_date |
1989-03-01T00:00:00Z |
| hierarchy_top_id |
NLEJ188987932 |
| id |
NLEJ203001397 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ203001397</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505223723.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1989 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ203001397</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1989</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">3</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary A total of 23 patients with high-risk acute myelogenous leukemia (AML) at diagnosis (2 patients), relapsing AML (14) or resistant AML (6) were treated with 25 μg/kg i. v. plicamycin every other day for 3 weeks and 500–4,000 mg hydroxyurea per day p. o. according to the WBC count. Aplasia was observed in only two patients. Severe extrahematologic toxicity included sepsis (four cases), vomiting (four patients), toxic hepatitis (three cases), and fibrinopenia (one patient). No partial or complete responses were observed. The 95% confidence interval limit of the overall response rate (CR+PR) was 0–14%.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Archimbaud, Eric</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Troncy, Jacques</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sebban, Catherine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guyotat, Denis</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Devaux, Yves</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">French, Martine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moriceau, Michel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Viala, Jean-Jacques</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fiere, Denis</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Cancer chemotherapy and pharmacology</subfield><subfield code="d">1978</subfield><subfield code="g">25(1989) vom: März, Seite 223-225</subfield><subfield code="w">(DE-627)NLEJ188987932</subfield><subfield code="w">(DE-600)1458488-8</subfield><subfield code="x">1432-0843</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:25</subfield><subfield code="g">year:1989</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:223-225</subfield><subfield code="g">extent:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF00689589</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">25</subfield><subfield code="j">1989</subfield><subfield code="c">3</subfield><subfield code="h">223-225</subfield><subfield code="g">3</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ188987932 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1432-0843 |
| topic_title |
Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
e a ea j t jt c s cs d g dg y d yd m f mf m m mm j j v jjv d f df |
| hierarchy_parent_title |
Cancer chemotherapy and pharmacology |
| hierarchy_parent_id |
NLEJ188987932 |
| hierarchy_top_title |
Cancer chemotherapy and pharmacology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ188987932 (DE-600)1458488-8 |
| title |
Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia |
| spellingShingle |
Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia |
| ctrlnum |
(DE-627)NLEJ203001397 |
| title_full |
Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia |
| journal |
Cancer chemotherapy and pharmacology |
| journalStr |
Cancer chemotherapy and pharmacology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1989 |
| contenttype_str_mv |
zzz |
| container_start_page |
223 |
| container_volume |
25 |
| physical |
3 |
| format_se |
Elektronische Aufsätze |
| title_sort |
phase ii trial of plicamycin and hydroxyurea in acute myelogenous leukemia |
| title_auth |
Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia |
| abstract |
Summary A total of 23 patients with high-risk acute myelogenous leukemia (AML) at diagnosis (2 patients), relapsing AML (14) or resistant AML (6) were treated with 25 μg/kg i. v. plicamycin every other day for 3 weeks and 500–4,000 mg hydroxyurea per day p. o. according to the WBC count. Aplasia was observed in only two patients. Severe extrahematologic toxicity included sepsis (four cases), vomiting (four patients), toxic hepatitis (three cases), and fibrinopenia (one patient). No partial or complete responses were observed. The 95% confidence interval limit of the overall response rate (CR+PR) was 0–14%. |
| abstractGer |
Summary A total of 23 patients with high-risk acute myelogenous leukemia (AML) at diagnosis (2 patients), relapsing AML (14) or resistant AML (6) were treated with 25 μg/kg i. v. plicamycin every other day for 3 weeks and 500–4,000 mg hydroxyurea per day p. o. according to the WBC count. Aplasia was observed in only two patients. Severe extrahematologic toxicity included sepsis (four cases), vomiting (four patients), toxic hepatitis (three cases), and fibrinopenia (one patient). No partial or complete responses were observed. The 95% confidence interval limit of the overall response rate (CR+PR) was 0–14%. |
| abstract_unstemmed |
Summary A total of 23 patients with high-risk acute myelogenous leukemia (AML) at diagnosis (2 patients), relapsing AML (14) or resistant AML (6) were treated with 25 μg/kg i. v. plicamycin every other day for 3 weeks and 500–4,000 mg hydroxyurea per day p. o. according to the WBC count. Aplasia was observed in only two patients. Severe extrahematologic toxicity included sepsis (four cases), vomiting (four patients), toxic hepatitis (three cases), and fibrinopenia (one patient). No partial or complete responses were observed. The 95% confidence interval limit of the overall response rate (CR+PR) was 0–14%. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia |
| url |
http://dx.doi.org/10.1007/BF00689589 |
| remote_bool |
true |
| author2 |
Archimbaud, Eric Troncy, Jacques Sebban, Catherine Guyotat, Denis Devaux, Yves French, Martine Moriceau, Michel Viala, Jean-Jacques Fiere, Denis |
| author2Str |
Archimbaud, Eric Troncy, Jacques Sebban, Catherine Guyotat, Denis Devaux, Yves French, Martine Moriceau, Michel Viala, Jean-Jacques Fiere, Denis |
| ppnlink |
NLEJ188987932 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth |
| up_date |
2024-07-06T09:31:03.025Z |
| _version_ |
1803821528411799552 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ203001397</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505223723.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1989 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ203001397</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1989</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">3</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary A total of 23 patients with high-risk acute myelogenous leukemia (AML) at diagnosis (2 patients), relapsing AML (14) or resistant AML (6) were treated with 25 μg/kg i. v. plicamycin every other day for 3 weeks and 500–4,000 mg hydroxyurea per day p. o. according to the WBC count. Aplasia was observed in only two patients. Severe extrahematologic toxicity included sepsis (four cases), vomiting (four patients), toxic hepatitis (three cases), and fibrinopenia (one patient). No partial or complete responses were observed. The 95% confidence interval limit of the overall response rate (CR+PR) was 0–14%.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Archimbaud, Eric</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Troncy, Jacques</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sebban, Catherine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guyotat, Denis</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Devaux, Yves</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">French, Martine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moriceau, Michel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Viala, Jean-Jacques</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fiere, Denis</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Cancer chemotherapy and pharmacology</subfield><subfield code="d">1978</subfield><subfield code="g">25(1989) vom: März, Seite 223-225</subfield><subfield code="w">(DE-627)NLEJ188987932</subfield><subfield code="w">(DE-600)1458488-8</subfield><subfield code="x">1432-0843</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:25</subfield><subfield code="g">year:1989</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:223-225</subfield><subfield code="g">extent:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF00689589</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">25</subfield><subfield code="j">1989</subfield><subfield code="c">3</subfield><subfield code="h">223-225</subfield><subfield code="g">3</subfield></datafield></record></collection>
|
| score |
7.401412 |